Penn spinout company Verismo Therapeutics has successfully raised $7 million in a pre-Series A round led by BRV Capital Management.
The funds will be used to advance Verismo’s clinical trials for its SynKIR-110 therapy, with the goal of treating aggressive solid tumor malignancies such as mesothelioma and ovarian cancer.
The funds will also be used to continue preclinical development for Verismo’s SynKIR-310 therapy for diffuse large B-cell lymphoma and may help to advance additional future therapies. Read more here.
In addition to the funding, Verismo also announced an expansion of its partnership with researchers at Penn Medicine. The expanded R&D alliance includes clinical cell manufacturing in partnership with the Clinical Cell and Vaccine Production Facility (CVPF) at the Perelman School of Medicine for clinical testing and potential use in a Phase I clinical trial to be conducted at Penn. Learn more here.